Skip to content
Sign up

Updated · published

Ledderhose disease (plantar fibromatosis): 2026 update

A hard lump under the arch of the foot, which does not always hurt, which grows slowly, and which almost everyone first takes for plantar fasciitis.

The essentials, in 30 seconds

A painful mass on weight-bearing, under the arch of the foot, suggests a benign fibromatosis with no causal treatment: the first measure is mechanical offloading of the nodule.

15.2%of men with Dupuytren's disease who also have plantar nodules

What it is
A benign superficial fibromatosis, with the same histology as Dupuytren's disease and Peyronie's disease.
What points the way
A firm nodule under the arch, bound to the fascia, which hardens when the toes are put under tension.
How it is settled
Ultrasound first line; MRI reserved for large, deep or doubtful forms.
What to do first
The most useful measure is mechanical offloading of the nodule.
When to refer
Refer without treating in the face of rapid growth of the mass, or a size greater than 5 cm.

What follows covers each of these points in detail, with sources. It is there if you need it.

This topic is taught in a course: Heel spur, plantar heel pain and tibialis posterior dysfunction, online with Anthony Baillon.

Chapter by chapter

1 / 11

10 article chapters · 35 min in total

Chapter 1

Understanding◔ 3 min

It is the same process as Dupuytren's disease, but in a foot that bears the weight of the body.

Cousin of Dupuytren's
The palmar and plantar forms share the same proliferation of fibroblasts and myofibroblasts.
No contracture
The plantar form produces painful nodules but does not usually lead to contracture, unlike the hand.
Site of the nodule
84 % of fibromas are located in the middle third of the plantar fascia, not under the heel.
No established cause
No aetiology is established: management remains symptomatic, never causal.
Chapter 2

Background◔ 5 min

In men with Dupuytren's disease, plantar nodules are found in 15.2 % of cases, versus 3.9 % in controls.

Uncertain prevalence
No survey in the general population has been published: the true prevalence remains unknown, an American estimate relating to the diagnosed disease.
Typical profile
In a series of 18 patients operated on, the mean age was 41.3 years and 12 were men; an American claims-based study counts 63 % women among new cases.
Odds ratio
The link with Dupuytren's disease gives an odds ratio of 4.35, measured against matched controls.
Revised diathesis
Ledderhose disease is not a formal criterion of diathesis in the revised version of the criteria.
Chapter 3

Multiple sites◔ 4 min

Three sites, one single process: palmar, plantar and penile forms share the same biology.

Shoes off
Have the shoes taken off a patient seen for a hand problem: 15.2 % of Dupuytren patients have plantar nodules.
Look at the palms
The converse is true: Ledderhose disease is among the risk factors for Dupuytren's disease.
Family history
A family history of Dupuytren's disease gives an odds ratio of 3.1 for plantar involvement.
Case by case
Each site is treated for itself: no systemic treatment is validated.
Chapter 4

Recognising◔ 3 min

The nodule is bound to the fascia: it does not roll like a lipoma and hardens with the windlass manoeuvre.

Typical complaint
A lump under the foot discovered when walking barefoot, with pain on prolonged weight-bearing.
Not fasciopathy
Unlike in fasciopathy, the pain is not maximal on the first step in the morning.
Windlass manoeuvre
Passive dorsiflexion of the toes makes the nodule more prominent and harder.
Multiple nodules
17 % of patients have several nodules from the outset, at the first consultation.
Chapter 5

Imaging◔ 2 min

A genuine plantar fibroma can look like a sarcoma on MRI, a real diagnostic trap.

Role of imaging
The diagnosis is clinical; ultrasound and MRI are only confirmatory adjuncts.
Ultrasound signs
Mixed echogenicity is found in 82 % of nodules, the comb sign in 51 %.
MRI reserved
MRI is requested for a large, deep or atypical lesion, when tumoral doubt persists.
The sarcoma trap
A “brain gyriform” pattern, specific to fibromyxoid sarcoma, was seen in a proven fibroma.
Chapter 6

Role of the physiotherapist◔ 5 min

Of 233 patients in 25 studies, only 35 received conservative treatment, against 178 operated on.

Offload the nodule
The orthosis with a cut-out and rigid footwear reduce weight-bearing pain through simple mechanical logic.
No trial
Nobody has measured this effect in this condition: it is mechanical reasoning, not proof.
Borrowed stretches
Triceps surae stretches are extrapolated from fasciopathy, not proven here.
Moderate evidence
Radiotherapy is the only treatment assessed in a randomised trial against placebo.
Chapter 7

Radiotherapy◔ 3 min

The LedRad trial shows relief in 74 % of irradiated patients versus 56 % under placebo.

Placebo-controlled trial
84 patients were randomised between radiotherapy and sham radiotherapy.
Widening gap
Pain at 18 months is 2.1 versus 3.4: the gap widens over time.
Long-term effect
Across 102 irradiated feet, mean pain fell from 5.7 to 1.7.
Complete response
41 % of feet had complete disappearance of pain after radiotherapy.
Chapter 8

Operating◔ 2 min

Recurrence depends on the width of the resection, and on nothing else: 67 % with local resection, 27 % after fasciectomy.

Local resection
Resection of the nodule alone recurs in 67 % of cases.
Fasciectomy
Fasciectomy of the whole affected fascia gives the lowest recurrence: 27 %.
Golden rule
Surgery comes after failure of conservative treatment, never before.
Asymptomatic nodule
An asymptomatic nodule is not operated on: the risk of recurrence is not worth the benefit.
Chapter 9

Case reports◔ 3 min

A 48-year-old man obtained complete disappearance of pain after three sessions of shockwaves.

Precise protocol
Three sessions one week apart, 2,000 pulses at 5 Hz, were applied.
Bilateral involvement
This 48-year-old patient had bilateral Ledderhose disease.
Scarcity of data
This case documents precise, reproducible parameters, which are rare in this field.
Chapter 10

In practice◔ 5 min

The toe contracture the patient fears is the exception, not the rule, unlike in the hand.

Map
Note the number of nodules, size in millimetres and distance from the heel: the only data useful for follow-up.
Red flags
Rule out first: rapid growth, size greater than 5 cm, night pain.
Examine the hands
One in seven men with Dupuytren's disease has plantar nodules: inspect systematically.
Who to refer to
The foot orthopaedic surgeon steps in for disabling pain despite offloading or for diagnostic doubt.
11

Train on this

Online

Lower limb

Heel spur, plantar heel pain and tibialis posterior dysfunction

Anthony Baillon

Next comes practice: the course that teaches this topic, with Anthony Baillon.

Our courses on this topic may be covered by DPC or FIFPL, the French continuing-education funding schemes, depending on your profession and situation.

Posted by

Anthony BAILLON

Physiotherapist


A hard lump under the arch of the foot, which does not always hurt, which grows slowly, and which almost everyone first takes for plantar fasciitis. Yet it is a different disease, a first cousin of Dupuytren's disease, for which a single treatment has been validated against placebo, and that treatment is neither surgery nor physiotherapy.

A synthesis written from primary sources checked one by one on PubMed: identifier resolved, journal and year verified, abstract read before citation. Complete bibliography at the end of the article.

Ledderhose disease in three figures

A strong family link with the hand, a treatment that has passed the placebo test, a surgery that recurs

Three key figures on Ledderhose disease 15.2 % of men with Dupuytren's disease have plantar nodules versus 3.9 % of controls; 74 % pain relief at twelve months under radiotherapy versus 56 % under placebo; 67 % recurrence after local resection. 15.2 % of men with Dupuytren's disease have plantar nodules, versus 3.9 % of controls Gudmundsson 2013, OR 4.35 74 % relieved at twelve months under radiotherapy, versus 56 % under placebo (p = 0.002) LedRad, phase 3 trial 67 % recurrence after local resection; 27 % after fasciectomy Anwander 2024, systematic review

Sources: Gudmundsson KG, Jónsson T, Arngrímsson R. Foot Ankle Int 2013;34(6):841-845 (PMID 23386754); de Haan A et al. Radiother Oncol 2023;185:109718 (PMID 37211283); Anwander H et al. Foot Ankle Spec 2024;17(2):109-116 (PMID 34369197).

Clinical summary

What to take away before reading the rest

  • What it is. A benign proliferation of fibroblasts and myofibroblasts in the plantar aponeurosis, forming nodules on the central or medial cord of the aponeurosis, most often in the middle third of the fascia. The histology is the same as in Dupuytren's disease, of which it is the plantar equivalent.
  • The major difference from the hand. Ledderhose disease does not usually cause contracture : the complaint is a painful mass on weight-bearing, not a toe that bends.
  • The link with Dupuytren's disease, in figures. 15.2 % of men with Dupuytren's disease in the Reykjavík cohort had plantar nodules, versus 3.9 % of matched controls (odds ratio 4.35). Looking at the feet of a Dupuytren patient, and at the hands of a Ledderhose patient, is not optional.
  • The diagnosis is clinical, confirmed by ultrasound. The nodule is attached to the fascia, moves with it, and hardens on dorsiflexion of the toes.
  • The only treatment validated against placebo is radiotherapy (a double-blind phase 3 randomised trial in 84 patients). No other treatment, surgery and physiotherapy included, has reached this level of evidence.
  • The trap not to be missed. A plantar mass is not always a fibroma. Low-grade sarcomas have been reported with this exact presentation, and conversely a genuine Ledderhose disease can mimic a sarcoma on MRI.

What is Ledderhose disease, and whose cousin is it?

Understanding what this disease is doing spares you a long detour: it is the same tissue as in the palm, at the same cellular stage, but in a foot that bears the weight of the body, and that last point changes almost everything else.

A superficial fibromatosis, cousin of Dupuytren's disease

Ledderhose disease belongs to the group of superficial fibromatoses, alongside Dupuytren's disease (palmar fibromatosis) and Peyronie's disease (penile involvement). All of them rest on the same process: a benign proliferation of fibroblasts and myofibroblasts, producing excess collagen.

A pathology review devoted to both sites describes a common histology, a bland spindle-cell proliferation of bluish appearance, with a variable amount of background collagen depending on the age of the lesion1. The authors above all stress the decisive clinical difference: palmar fibromatosis leads to nodules and then to digital contracture, whereas plantar fibromatosis produces often painful nodules but does not usually lead to contracture1.

This is the nuance to explain to the patient who has a relative who has had hand surgery and who fears being “no longer able to straighten the toes”. Toe contracture exists, but it is rare2 ; what causes the trouble is the lump under the foot.

Where exactly the nodules sit

The topography is stereotyped and it is a diagnostic argument. The nodules sit on the central or medial cord of the plantar aponeurosis, in proportions that vary between series: an old, small ultrasound series (14 patients, 25 nodules) found them medial in 60 % of cases and central in 40 %21, whereas the largest MRI series, retrospective and from a tertiary centre (196 cases), finds the central cord involved in 83 % of cases and the medial cord in 15 %, with several cords involved in 14 % of cases22. Along the length of the fascia, an ultrasound series of 57 fibromas in 43 patients measured their distribution: 84 % were located in the middle third of the plantar fascia3.

This detail explains two things. First, why the pain is not at the heel: it lies under the arch, in front of the heel, exactly where plantar fasciitis does not hurt. Second, why footwear and weight-bearing govern the complaint: a nodule in the middle of the arch is crushed at every step between the ground and the bone.

A cause that remains unknown, associations that are not

No aetiology is established, and the reviews say so bluntly: there is no causal treatment, management remains symptomatic2. The associations reported in the literature are, for their part, fairly consistent from one review to another: trauma, diabetes, anticonvulsant use, adhesive capsulitis of the shoulder, alcohol consumption and liver disease4.

They must be handled with the caution appropriate to associations drawn from case series: they guide the history, they do not explain the disease, and they are not treated. The only link whose magnitude has been measured in a cohort with a control group is the one with Dupuytren's disease, and that is the subject of the next chapter.

Ledderhose disease is not a plantar fasciitis that has gone wrong: it is a disease of the hand that has ended up on the wrong floor.

Key points

  • Benign superficial fibromatosis, with the same histology as Dupuytren's disease and Peyronie's disease.
  • Nodules of the central or medial cord of the aponeurosis, in the middle third in 84 % of cases: under the arch, not under the heel.
  • Unlike in the hand, contracture is the exception : the complaint is a painful mass on weight-bearing.
  • No established cause, no causal treatment : everything that follows is symptomatic.

Who is affected, and what is the link with Dupuytren's disease?

This is the most useful chapter in the clinic, because it turns a curiosity into an examination reflex: two sites to look at in the same patient, in both directions.

A rare disease, whose exact prevalence remains poorly known

We must begin with some methodological honesty: no prevalence survey in the general population has been published, to our knowledge. Reviews quote incidence figures of the order of one to two cases per hundred thousand people, but these values come from hospital series and not from a representative sample4. An American study based on claims data linked to medical records, whose authors are employees or consultants of a pharmaceutical company (Endo) and employees of a research firm (IQVIA), estimates the prevalence of diagnosed plantar fibromatosis at 57 cases per 100,000 in 2021; the study identifies cases by diagnosis codes, which may confuse them with those of plantar fasciitis (a limitation that we add)23. The profile described by hospital series is that of a middle-aged or older adult, with a male predominance; among the 620 new cases of the American study, however, 63 % were women, which may reflect, in our view, healthcare use23.

Surgical series give consistent benchmarks. In a British series of 18 patients operated on with a partial fasciectomy, the mean age was 41.3 years (range 20 to 57), with 12 men out of 18, and 17 % of patients had multiple nodules at the first consultation5. Cohen's ultrasound series included 43 patients aged 26 to 77 years, with a mean age of 54 years3.

This is the most solid piece of data in the whole chapter, and it comes from the Reykjavík study. One hundred and twenty-two men with Dupuytren's disease were re-invited eighteen years after their initial inclusion, along with as many controls matched for age and smoking. Ninety-two patients and 101 controls attended and were examined for plantar nodules6.

Ledderhose disease was identified in 14 of the 92 men with Dupuytren's disease (15.2 %), versus 4 of the 101 controls (3.9 %), an odds ratio of 4.35 (95 % confidence interval: 1.3 to 16.7; p < 0.01). Two secondary findings deserve as much attention:

  • Men operated on for their Dupuytren's disease, or with a digital contracture, had six times the risk of having plantar nodules compared with those who had only palmar nodules or cords (odds ratio 6.1; 1.8 to 27.1; p < 0.001)6.
  • Plantar involvement was linked to a family history of Dupuytren's disease (odds ratio 3.1; 1.1 to 8.5; p = 0.02)6.

The converse was observed in a Dutch prevalence study of 763 randomly selected subjects aged 50 to 89 years: the prevalence of Dupuytren's disease there reached 22.1 %, and the presence of Ledderhose disease was among the significant risk factors for Dupuytren's disease, alongside a history of hand trauma, excessive alcohol consumption and family history7.

Plantar nodules: Dupuytren's disease versus matched controls

Reykjavík cohort, clinical examination of the feet at 18 years of follow-up: 92 affected men, 101 controls matched for age and smoking

Frequency of plantar nodules according to the presence of Dupuytren's disease 15.2 % in men with Dupuytren's disease versus 3.9 % in controls, odds ratio 4.35. The risk rises to an odds ratio of 6.1 in patients who have been operated on or who have a digital contracture. Proportion of men with plantar nodules Dupuytren's disease (n = 92) 15.2 % Matched controls (n = 101) 3.9 % Measured odds ratios (logarithmic scale, line = 95 % confidence interval) 1251030 Dupuytren vs controls 4.35 Operated on or contracted 6.1

Source: Gudmundsson KG, Jónsson T, Arngrímsson R. Association of Morbus Ledderhose with Dupuytren's contracture. Foot Ankle Int 2013;34(6):841-845 (PMID 23386754). Confidence intervals: 1.3-16.7 for the first ratio, 1.8-27.1 for the second.

The nuance about “diathesis”, which needs quoting correctly

The notion of Dupuytren's diathesis refers to the clinical features that identify aggressive forms at high risk of recurrence. Its historical version counted ectopic involvement (that is, outside the palm, hence plantar or penile) among its four factors.

A reassessment carried out in 322 patients modified this definition, and the detail matters: the factors were broadened to include male sex and an age at onset below 50 years, but ectopic involvement was restricted to the pads of the interphalangeal joints (Garrod's pads) alone. The presence of all the revised factors raises the risk of recurrence to 71 %, versus 23 % in a patient who has none8.

In other words: Ledderhose disease is not, in the revised version, a formal criterion of diathesis. But the Reykjavík study shows that it preferentially accompanies the most severe palmar forms6. The practical approach is the same under both readings (look at the other site), but the exact wording avoids making a score say what it does not say.

Four benchmarks from the field

Values drawn from the series cited: these are clinical orders of magnitude, not population rates

Four secondary statistics on plantar fibromatosis Mean age 41 years in a surgical series, 54 years in an ultrasound series; 84 % of nodules in the middle third of the fascia; multiple nodules in 17 % of patients; intralesional Doppler vascularity in 53 % of cases. 41 / 54 mean ages (years) surgical series / ultrasound series Kadir 2017 · Cohen 2018 84 % in the middle third of the plantar fascia, 57 nodules measured Cohen 2018 17 % multiple nodules at the first consultation Kadir 2017 53 % vascularity within the lesion on Doppler: it is common Cohen 2018

Sources: Kadir HKA, Chandrasekar CR. Foot 2017;31:31-34 (PMID 28334642); Cohen BE, Murthy NS, McKenzie GA. J Ultrasound Med 2018;37(11):2725-2731 (PMID 29603334).

Key points

  • No survey in the general population: the exact prevalence is unknown ; the incidence figures quoted in reviews come from hospital series, and an American study based on claims data estimates the prevalence of the diagnosed disease at 57 per 100,00023.
  • 15.2 % versus 3.9 % : the link with Dupuytren's disease is measured, with an odds ratio of 4.35.
  • The risk rises to 6.1 in patients who have had hand surgery or who have a digital contracture: these are the ones whose shoes must come off.
  • In the revised diathesis, the ectopic involvement retained is that of Garrod's pads, not plantar involvement. Quote the score correctly.

What changes when several sites are involved?

Some patients do not have Ledderhose disease: they have a fibromatous disease that expresses itself in several places. This subpopulation deserves to be identified, because it changes the examination, the prognosis and the message.

Three sites, one single process

Superficial fibromatoses form a histologically coherent group. A pathology review devoted to the palmar and plantar forms describes in both the same proliferation of fibroblasts and myofibroblasts, with a common microscopic appearance: bland spindle cells of bluish appearance, with a quantity of background collagen that varies with the age of the lesion1. Clinical reviews add the third site, penile, under the name of Peyronie's disease4.

What distinguishes these three expressions is the mechanical behaviour of the tissue involved, not the nature of the lesion:

The three superficial fibromatoses. The elements cited correspond to what the referenced sources report; this is not a formal classification.
SiteNameWhat the lesion doesMain clinical consequence
Palmar aponeurosisDupuytren's diseaseNodules, then longitudinal cords that contract1Digital contracture, loss of finger extension
Plantar aponeurosisLedderhose diseaseNodules of the aponeurosis, middle third in 84 % of cases3 ; unusual contracture1Mass painful on weight-bearing, discomfort in footwear
Penile tunica albugineaPeyronie's diseaseFibrous plaque of the tunica albuginea4Deformity on erection, pain

The difference between the hand and the foot deserves to be explained to the patient, because it explains why the treatment differs. In the palm, the cord pulls on a mobile finger and surgery has a geometric objective: to restore extension. Under the foot, the nodule is crushed against the ground and surgery has an analgesic objective: to remove the compression. The two diseases share a histology and not a therapeutic logic.

How to spot this patient in the clinic

Three actions are enough, and none takes more than a minute:

  • Have every patient who consults for a hand take their shoes off. In the Reykjavík cohort, 15.2 % of men with Dupuytren's disease had plantar nodules, versus 3.9 % of matched controls6.
  • Look at the palms of every patient who consults for a foot. The converse is documented at population level: in a Dutch study of 763 subjects aged 50 to 89 years, the presence of Ledderhose disease was among the significant risk factors for Dupuytren's disease7.
  • Ask about family history. Plantar involvement was linked to a family history of Dupuytren's disease with an odds ratio of 3.1 (1.1 to 8.5; p = 0.02)6.

The strongest signal, however, is not the mere presence of palmar involvement: it is its severity. Men operated on for their Dupuytren's disease, or with an established digital contracture, had six times the risk of having plantar nodules compared with those who had only nodules or cords (odds ratio 6.1; 1.8 to 27.1; p < 0.001)6. In other words, the patient whose shoes should come off first is the one who has already had hand surgery.

What this changes, and what it does not

What this changes. The examination becomes systematically bilateral and multi-site. Follow-up lengthens, because one site can appear years after the other: the Icelandic cohort re-examined its patients eighteen years after inclusion6. And the message changes: we no longer talk about an isolated nodule but about an underlying predisposition, which helps the patient understand why the disease comes back after surgery.

What this does not change. The treatment of each site remains that of that site. No data indicate that a systemic treatment acts on the whole, and the drugs cited in the reviews (verapamil, tamoxifen, imatinib, sorafenib, mitomycin C) are cited at descriptive levels of evidence, with no established indication49.

Quoting the diathesis without making it say more than it does

The revised version of Dupuytren's diathesis, established in 322 patients, has restricted the ectopic involvement criterion to the pads of the interphalangeal joints (Garrod's pads), and added male sex and onset before 50 years. The presence of all the revised factors raises the risk of recurrence to 71 %, versus 23 % in their absence8. Ledderhose disease therefore does not appear there by name as a criterion, which takes nothing away from its measured association with severe palmar forms6. To say “your plantar involvement is part of your diathesis” is an approximation; to say “it more often accompanies the forms of the hand that recur” is accurate.

Key points

  • One single disease, three expressions: palm, sole, penis (same histology, different mechanics and treatments).
  • The patient whose shoes should come off first is the one who has already had hand surgery : odds ratio 6.1.
  • Plantar involvement is linked to the family history of Dupuytren's disease (odds ratio 3.1).
  • No validated systemic treatment: each site is treated for itself.

How do you recognise a plantar nodule at examination?

Ultrasound and MRI of the foot: nodule of the plantar fascia delineated by arrows, plantar fibromatosis.

UltrasoundUltrasound and MRI of the foot: nodule of the plantar fascia delineated by arrows, plantar fibromatosis.

Source : Van Hul et al., Insights into imaging, 2011, figure 16 · CC BY

The diagnosis is clinical. It comes down to a well-conducted palpation and three questions, provided you keep in mind what it must above all not be confused with.

What the patient describes

Three complaints recur, in this order of frequency: a lump under the foot that the patient discovered while washing or walking barefoot, pain on weight-bearing that increases with prolonged standing and barefoot walking on hard ground, and discomfort in footwear. Kadir's surgical series summarises the reasons for consultation in three items: pain, swelling, and functional discomfort5.

What is not the clinical picture: pain on the first steps on waking, maximal under the heel, easing after a few minutes of walking. That is the picture of plantar fasciopathy, and the distinction is the first one to make.

Palpation, step by step

  • Patient prone, knee flexed to 90°, foot relaxed: this is the position that gives the best access to the plantar surface without putting it under tension.
  • Palpate the whole aponeurosis from the heel towards the toes, without limiting yourself to the medial border. The nodule is firm, well defined, from a few millimetres to a few centimetres, often in the middle third: 84 % of lesions in an ultrasound series of 57 fibromas3.
  • Assess mobility. The nodule is bound to the fascia : it does not roll under the finger like a lipoma and does not follow the skin, which remains free above it.
  • Put the fascia under tension by passive dorsiflexion of the toes (windlass manoeuvre). The nodule becomes more prominent and harder, which confirms that it belongs to the aponeurosis.
  • Count and map. Multiple nodules are not rare: 17 % of the patients in Kadir's series had several from the outset5. Recording the number, the size and the distance from the heel makes it possible to follow the course without repeated imaging.
  • Examine the other foot, then both hands. Bilateral involvement is common4, and looking for an associated Dupuytren's disease is not a curiosity: it concerns one man in seven in the Reykjavík cohort6.
  • Look for toe contracture (rare, but it changes management because it marks an advanced form)1.

What it gets confused with

Differential diagnoses of a plantar mass or pain. The elements cited correspond to what the referenced sources report.
DiagnosisWhat suggests itWhat distinguishes it from plantar fibroma
Plantar fasciopathyFirst-step pain, maximal at the calcaneal insertion, loosening up with walkingNo palpable mass; heel pain rather than mid-plantar pain
Fibroma of the tendon sheathFirm mass in contact with a flexor tendonNot part of the aponeurosis; does not harden with the windlass manoeuvre
Synovial cyst or ganglionFluctuant, transilluminable mass, often of rapid onsetAnechoic fluid content on ultrasound
Morton's neuromaForefoot pain between the metatarsal heads, radiating to the toes, Mulder's signAnterior location, no fascial mass; see the dedicated article on the site
Bursitis or plantar callosityPoint of excessive loading, overlying hyperkeratosisSuperficial skin lesion, moving with the skin
Foreign body, granulomaHistory of skin breach, local inflammationContext, inflammatory signs, imaging
Soft-tissue sarcomaRapid growth, size greater than 5 cm, night pain, deep fixed massAbsolute red flag: sarcomas have been mistaken for plantar fibromas19

Red flags: do not treat, refer

  • Rapid growth of a plantar mass, or size greater than 5 cm.
  • Night pain that is non-mechanical and not relieved by offloading.
  • A mass that is deep, fixed to the deep planes, or that does not harden when the fascia is put under tension.
  • General signs : weight loss, fever, lymphadenopathy.
  • Personal history of neoplasia.
  • Reminder from the literature: an extraskeletal myxoid chondrosarcoma of the medial arch was initially mistaken for a plantar fibroma in a 44-year-old man19. At the slightest doubt, imaging and specialist opinion come before any local treatment.

Which imaging, and when should something else be feared?

MRI (a, b) and ultrasound (c, d) of the foot: fusiform thickening of the distal plantar fascia, low signal on MRI and hypoechoic on ultrasound, with hypervascularity on Doppler, Ledderhose disease.

MRIMRI (a, b) and ultrasound (c, d) of the foot: fusiform thickening of the distal plantar fascia, low signal on MRI and hypoechoic on ultrasound, with hypervascularity on Doppler, Ledderhose disease.

Source : Draghi et al., Insights into Imaging, 2017, figure 5 · CC BY

Imaging does not make the diagnosis; it confirms it and, above all, it rules things out. Two publications are enough to know what to request and how to read the report.

Ultrasound first line

The reviews agree: the diagnosis is clinical, and ultrasound and MRI are confirmatory adjuncts, MRI being reserved for aggressive or advanced forms49. Ultrasound has the advantage of being dynamic, comparative and immediate.

The reference series described 57 fibromas in 43 patients and quantified the ultrasound signs3 :

What ultrasound shows in plantar fibromatosis

57 nodules in 43 patients: frequency of each sign

Ultrasound signs of plantar fibromatosis Location in the middle third 84 %, mixed echogenicity 82 %, posterior enhancement 65 %, intralesional vascularity 53 %, comb sign 51 %. Location in the middle third of the fascia Mixed echogenicity Posterior acoustic enhancement Intralesional vascularity “Comb sign” (alternating bands) 84 % 82 % 65 % 53 % 51 % The comb sign (alternating hypoechoic and isoechoic bands) is more frequent in large nodules (p < 0.05).

Source: Cohen BE, Murthy NS, McKenzie GA. Ultrasonography of Plantar Fibromatosis: Updated Case Series, Review of the Literature, and a Novel Descriptive Appearance Termed the “Comb Sign”. J Ultrasound Med 2018;37(11):2725-2731 (PMID 29603334).

Two points of interpretation deserve to be stressed, to the patient as to the prescriber. First, intralesional vascularity on Doppler is not a sign of malignancy here : it is present in more than half of the benign fibromas of this series3. Second, the comb sign (this alternation of hypoechoic and isoechoic bands described by these authors) appears all the more readily the larger the nodule, which makes it a useful but not indispensable sign.

MRI, and the trap it holds

MRI is requested when the lesion is large, deep, atypical, or when tumoral doubt persists. It has, however, a shortcoming that must be known before reading an alarming report.

A case published in The Foot concerns a 42-year-old man with a plantar fibromatosis proven histologically, whose MRI showed a so-called “brain gyriform” pattern, an appearance until then described as specific to low-grade fibromyxoid sarcoma. The posterior acoustic enhancement on ultrasound, the T2 hyperintensity and the contrast enhancement were all atypical, and corresponded histologically to areas of high cellularity alternating with fibrous areas poor in cells20.

The practical message is twofold, and it goes both ways: a genuine plantar fibroma can look like a sarcoma on MRI, and a sarcoma can be mistaken for a plantar fibroma19. No imaging replaces pathology when the presentation is out of the ordinary. It is not for the physiotherapist to decide; it is for the physiotherapist to know when not to treat.

Key points

  • Diagnosis clinical : a firm nodule under the arch, bound to the fascia, which hardens when the toes are put under tension.
  • Ultrasound first line ; MRI for large, deep or doubtful forms.
  • Intralesional Doppler vascularity is common (53 %) and does not in itself suggest malignancy.
  • Imaging can be wrong in both directions : atypical mass = pathology, no blind local treatment.

What can physiotherapy do, and what belongs elsewhere?

This is a disease in which the physiotherapist is often the first to be consulted and rarely the one who will treat it. Knowing what can be offered, and when to hand over, is worth more than multiplying sessions on a nodule that will not budge.

The state of the evidence, without embellishment

The most complete systematic review of treatments collated 25 studies and 233 patients. Within this set, only five studies concerned a conservative treatment, totalling 35 patients, against 178 patients operated on15. The authors conclude that clinical trials with standardised outcome measures are still needed to seriously evaluate the success rate and the complications of each procedure.

An older review already stated it: no causal therapy exists, management is symptomatic and graded according to severity, and no long-term randomised controlled study was available for conservative options2. Since then, one exception has appeared, and only one: radiotherapy, which has its own chapter further down.

What rehabilitation actually aims at

Objective 1: offload the nodule. This is the measure whose effect is the most immediate and the most reproducible in practice. A plantar orthosis with a cut-out under the nodule, a cushioning insole, footwear with a thick, rigid sole: anything that stops the nodule from being crushed between the ground and the bone reduces weight-bearing pain. No trial has measured this effect in this condition: it is mechanical reasoning, and it must be presented as such.

Objective 2: maintain the flexibility of the posterior chain. A short triceps surae increases the strain on the aponeurosis. Stretches of the gastrocnemius and soleus, and the specific plantar fascia stretch, are commonly offered. Here again, there are no data specific to Ledderhose disease: the transposition comes from plantar fasciopathy, which is a different disease of the same tissue.

Objective 3: monitor. This is a fully fledged physiotherapist's task and it is underestimated. Mapping the nodules, measuring them, noting their number: that is what will make it possible to say in six months whether the disease is progressing, and that is what will trigger referral.

What to avoid. Aggressive techniques directly on the nodule (firm deep transverse massage, prolonged ischaemic pressure, radial shockwaves aimed at “breaking it up” without an established protocol) have no data in their favour and risk a painful worsening of a lesion that, for its part, does not dissolve under the finger. This point rests on reasoning, not on a trial: there is none.

Shockwaves: a special case, not to be confused with massage

Shockwaves of the focused high-energy type have been the subject of a small prospective series: six patients, two sessions seven days apart, 2,000 pulses at 3 Hz and 1.24 mJ/mm². Pain fell from 6 ± 2 before treatment to 2 ± 1 at fourteen days and then 1 ± 1 at three months, with all patients reporting softening of the nodules, without adverse effects12. A case report published in 2024 describes a comparable result in a 48-year-old man with bilateral involvement, with a different protocol: three weekly sessions, 2,000 pulses at 5 Hz and 0.20 mJ/mm²13. Six patients plus one case, without a control group, do not amount to proof: they make a serious lead, with published parameters, and the authors themselves call for larger trials12.

The table of modalities, with the level of evidence actually available

The ranking below applies GRADE principles to the specific question of symptomatic treatment of Ledderhose disease. It is an editorial judgement : to our knowledge, no published GRADE assessment exists for this condition. A consensus recommendation from the German society of radiation oncology (DEGRO 2015) covers radiotherapy for Ledderhose disease among other non-malignant conditions, with levels of evidence from 2c to 4 and grades A to C for all of these conditions24 ; for the rest, the ranking below is entirely our own.

Moderate

Radiotherapy for symptomatic nodules. The only treatment assessed in a double-blind phase 3 randomised placebo-controlled trial: pain relief in 74 % versus 56 %, a significant difference at 12 and 18 months, with quality of life and barefoot walking speed improved10. Downgraded from “high” for sample size (84 patients) and the absence of independent replication.

Low

Mechanical offloading : plantar orthosis with a cut-out under the nodule, cushioning insole, suitable footwear. Consistent with the pain mechanism and without risk, but no study has measured it in this indication. Recommended by the reviews as part of graded symptomatic treatment2.

Low

Excision surgery, reserved for failure of conservative treatment. Effective on symptoms, but recurrence depends directly on the extent of the resection: 67 % after local resection, 42 % after wide resection, 27 % after fasciectomy16. Retrospective series only.

Very low

Focused high-energy shockwaves. A prospective series of six patients12 and a case report13, both without a control group. Parameters published, adverse effects not reported, but the sample size rules out any conclusion on efficacy.

Very low

Corticosteroid injection, with or without intralesional fenestration. Two case reports describe a reduction in pain and volume at twelve months after two injections of triamcinolone combined with fenestration14. The authors themselves point out that this option has received only marginal attention in the literature.

Very low

Collagenase from Clostridium histolyticum. Described only in isolated case reports, including an ultrasound-guided injection for a recurrence1718. No comparative series, no validated indication in the foot.

Very low

Topical verapamil, tamoxifen, imatinib, sorafenib, mitomycin C. Cited by the reviews as options documented at varying levels of evidence, essentially descriptive49. None falls within physiotherapy and none has an established indication.

No evidence

Stretching and flexibility work of the posterior chain in this indication: no study. Extrapolated from plantar fasciopathy, which is a different disease of the same tissue. Without risk, but to be presented for what it is.

No evidence

Firm deep transverse massage and ischaemic pressure on the nodule. No data, no plausible mechanism for resorption of mature fibrous tissue, and a risk of painful worsening of a lesion that is already compressed at every step.

Key points

  • The conservative literature on this disease comes down to five studies and 35 patients (physiotherapy has never been evaluated in them).
  • The most useful measure is mechanical offloading of the nodule, and it must be presented as reasoning, not as proof.
  • The focused high-energy shockwaves have published parameters and six patients behind them. It is a lead, not an established protocol.
  • Do not hammer away at the nodule: nothing shows that it can be dissolved, and it is already crushed at every step.

Does radiotherapy really work?

This is the only question in this article that a placebo-controlled randomised trial answers. It deserves to be treated in detail, because it is also the treatment that patients fear most.

The LedRad trial, and why it counts

The LedRad study is a prospective multicentre randomised double-blind phase 3 trial. Patients were allocated to radiotherapy or to sham radiotherapy: a placebo, therefore, which is exceptional in this field. The primary outcome measure was pain reduction at twelve months on a numerical scale10.

Eighty-four patients were included. The results:

  • Pain at 12 months : 2.5 in the irradiated group versus 3.6 in the placebo group (p = 0.03).
  • Pain at 18 months : 2.1 versus 3.4 (p = 0.008); the gap widens over time rather than fading.
  • Pain relief at 12 months : 74 % versus 56 % (p = 0.002).
  • Quality of life significantly higher in the irradiated group (p < 0.001), and barefoot walking speed and cadence higher (p = 0.02).
  • Adverse effects : erythema, dry skin, burning sensations and transient worsening of pain, of mild grade in 95 % of cases, and resolved in 87 % of patients at eighteen months10.

LedRad: radiotherapy versus sham radiotherapy

Double-blind phase 3 randomised trial, 84 patients: mean pain on a numerical scale

LedRad trial results on pain Pain 2.5 versus 3.6 at twelve months and 2.1 versus 3.4 at eighteen months; relief obtained in 74 % versus 56 % of patients. ■ radiotherapy ■ sham (placebo) 0246 2.5 3.6 12 months p = 0.03 2.1 3.4 18 months p = 0.008 Mean pain on a numerical scale: the gap widens between 12 and 18 months. Relief at 12 months 74 % irradiated 56 % placebo p = 0.002 Adverse effects 95 % mild grade 87 % resolved at 18 months erythema, dry skin, burning, transient pain

Source: de Haan A, van Nes JGH, Kolff MW et al. Radiotherapy for Ledderhose disease: results of the LedRad-study. Radiother Oncol 2023;185:109718 (PMID 37211283).

What becomes of the effect in the long term

The same team surveyed by questionnaire all the patients treated with radiotherapy in its centre between 2008 and 2017. One hundred and two feet were irradiated in 67 patients (28 men, 39 women), according to a protocol of two series of five daily fractions of 3 Gy11.

Mean pain fell from 5.7 before treatment to 1.7 at the time of evaluation (p < 0.001). The detail of the response is more instructive than the mean: complete response (disappearance of pain) for 42 feet (41 %), partial response for 38 feet (37 %), no change for 22 feet (22 %), and worsening for none. Seventy-eight per cent of patients said they were satisfied, 57 % did not find the treatment burdensome, and quality-of-life scores were comparable to those of the Dutch population of the same age. The most frequent residual adverse effect was dry skin, in 10 patients (15 %)11.

One patient in five gets nothing from radiotherapy, none comes out worse, and two in five no longer have any pain at all: it is the only treatment of this disease for which this can be stated with a figure.

What the physiotherapist can say about it to the patient

The word “radiotherapy” evokes cancer, and many patients refuse before listening. Three factual elements are enough to restore a sense of proportion: it involves low doses (two series of five 3 Gy sessions in the published protocol11), the reported adverse effects are cutaneous and mild in 95 % of cases and resolved in 87 % of patients at eighteen months10, and it is the only treatment of this disease to have been compared with a placebo in a double-blind design. The decision rests with the doctor; the factual information, for its part, is given in the session.

Key points

  • Radiotherapy is the only treatment validated against placebo in this disease (phase 3, double-blind trial, 84 patients).
  • 74 % relief versus 56 % at twelve months, with a gap that widens at eighteen months.
  • In the long-term follow-up cohort: 41 % complete response, 37 % partial response, 0 % worsening.
  • Adverse effects cutaneous, mild in 95 % of cases, resolved in 87 % of patients at eighteen months.

When do you operate, and why is recurrence the rule?

Surgery relieves, and it recurs. These two facts do not contradict each other: they are explained by a single variable, the extent of what is removed.

Recurrence depends on the width of the resection, and on nothing else

This is the most useful result in the whole surgical literature on this disease. A systematic review combined with a personal series compiled six studies covering 109 feet in 92 patients, and classified recurrence according to the procedure performed16 :

Recurrence after surgery, by extent of resection

Systematic review of six studies, 109 feet in 92 patients

Recurrence rate of plantar fibromatosis by surgical procedure 67 % recurrence after local resection, 42 % after wide resection, 27 % after fasciectomy. The more extensive the resection, the less the disease returns. 0 %25 %50 %75 % 67 % Local resection the nodule alone 42 % Wide resection nodule and margins 27 % Fasciectomy the whole affected fascia

Source: Anwander H, Weichsel F, Cullmann J et al. Recurrence Rate After Wide Resection of Plantar Fibromatosis: A Case Series and Systematic Literature Review. Foot Ankle Spec 2024;17(2):109-116 (PMID 34369197).

The authors draw an explicit recommendation from this: prefer wide resection or fasciectomy to local resection, because of the markedly lower recurrence rate16. Their own series of 12 patients reviewed between 2 and 13 years after a wide resection shows 2 recurrences (17 %) at a mean follow-up of 7.8 years, with a median foot functional index (Foot Functional Index) of 1 and a median AOFAS score of 95; in other words, excellent functional results in those who do not relapse.

A British series offers a useful counterpoint. Eighteen patients, nineteen partial fasciectomies, with up to five years of follow-up: only one recurrence (6 %), but 17 % scar problems (two cases of scar pain and one hypersensitive scar resolved at twelve months)5. This last point is not trivial in a region that bears body weight: a painful plantar scar can be more disabling than the nodule it has replaced.

Who to operate on, and when

The rule accepted by all the reviews is simple: surgery comes after failure of conservative treatment, never before915. The criteria that tip the balance:

  • disabling weight-bearing pain despite offloading, a suitable orthosis and footwear adaptation;
  • a large nodule, or one with documented progression over several months;
  • established toe contracture (rare, but it changes the functional situation);
  • persistent diagnostic doubt, where excision also has pathological value.

And a common-sense contraindication that the literature suggests through its figures: an asymptomatic nodule is not operated on. A two-in-three recurrence rate after local resection is not a reasonable price to pay to remove a lump that does not hurt.

Key points

  • Recurrence follows the extent of the resection: 67 % local, 42 % wide, 27 % after fasciectomy.
  • The systematic review explicitly recommends wide resection or fasciectomy rather than excision of the nodule alone.
  • Functional results in patients without recurrence are excellent (median AOFAS 95), but 17 % scar problems have been reported after partial fasciectomy.
  • A painless nodule is not operated on.

What do real case reports teach us?

Four published situations, taken as they are with their identifiers. Two show what treatment can do, two show what imaging cannot.

Case 1: Bilateral involvement treated with shockwaves

Fulceri F, Ryskalin L, Morucci G et al. Life 2024;14(2):16913 (free full text, PMC10889909).

A 48-year-old man presents with bilateral Ledderhose disease. The protocol applied comprised three sessions one week apart, 2,000 pulses at 5 Hz, energy flux density of 0.20 mJ/mm², with ultrasound follow-up. The reported result is complete disappearance of pain, restoration of full functional activity and a marked improvement in quality of life.

What this case teaches, and what it does not. It documents precise, reproducible parameters, which this field sorely lacks; the authors themselves note that the literature on shockwaves in this indication is “extremely limited” and that no optimal parameter has been defined. But a single case without a control group, in a disease that fluctuates, does not demonstrate efficacy.

Case 2: Two nodules treated with fenestration and corticosteroids

Flanagan G, Burt N, Reilly IN. SAGE Open Med Case Rep 2021;9:2050313X21101181314 (free full text, PMC8107658).

Two patients with painful plantar nodules each received, on two occasions, an intralesional fenestration combined with an injection of triamcinolone acetonide mixed with a local anaesthetic. At twelve months, the authors report a significant reduction in pain and in lesion volume.

What this case teaches. The authors open their article by noting that corticosteroid injection has received, in this disease, no more than a passing mention in the scientific literature. This is exactly the problem of the field: widespread practices, almost never evaluated. Two patients do not change this observation, but they describe a protocol that others will be able to reproduce.

Case 3: A sarcoma mistaken for a plantar fibroma

Lockyer MG, Rosen DG. Anticancer Res 2015;35(11):6171-617419.

A 44-year-old man presents with a mass of the medial arch of the foot, initially considered to be a plantar fibroma. MRI showed a lobulated subcutaneous mass, inseparable from the fascia. Microscopic examination revealed an extraskeletal myxoid chondrosarcoma (a rare tumour, indolent in course but with a high potential for local recurrence and metastasis).

What this case teaches. The authors conclude that this diagnosis must always be considered in the presence of a mass of the plantar fascia. For the physiotherapist, the translation is direct: a plantar mass that grows, that exceeds a few centimetres or that comes with night pain is not treated; it is referred.

Case 4: A plantar fibroma that, for its part, looked like a sarcoma

Touraine S, Bousson V, Kaci R et al. The Foot 2013;23(2-3):88-9220.

A 42-year-old man with a plantar fibromatosis histologically proven showed on MRI a “brain gyriform” pattern previously described as exclusive to low-grade fibromyxoid sarcoma, with posterior acoustic enhancement on ultrasound, T2 hyperintensity and contrast enhancement, all of them atypical. Histology showed that this pattern corresponded to the juxtaposition of highly cellular areas and fibrous areas poor in cells.

What this case teaches. This is the exact mirror of the previous one, and the two go together. Imaging is wrong in both directions; only pathology settles it. An alarming MRI report no more condemns the patient than a reassuring report puts them out of harm's way.

Key points

  • The conservative treatments of this disease that are best described rest on case reports, not on trials: telling the patient so is part of consent.
  • Two symmetrical cases remind us that imaging is wrong in both directions (a sarcoma mistaken for a fibroma, a fibroma resembling a sarcoma).
  • Faced with an atypical mass, the physiotherapist's course of action is not to decide but to refrain from treating and refer.

How do you apply all this from Monday morning?

A rare disease, for which the only learned-society recommendation found concerns a treatment that does not fall to us, radiotherapy: the physiotherapist's role in it is real, but it must be defined precisely so as not to stray into useless sessions.

The first session, in six points

  1. Name and distinguish. Tell the patient that it is not plantar fasciitis, that it is the plantar cousin of Dupuytren's disease, and that the toe contracture the patient fears is the exception and not the rule1.
  2. Map. Number of nodules, size in millimetres, distance from the posterior border of the heel, side. This is the only piece of data that will make it possible to follow the course without multiplying imaging.
  3. Examine the hands, and the other foot. One in seven men with Dupuytren's disease has plantar nodules6 ; the converse justifies inspecting the palms of every Ledderhose patient.
  4. Rule out the red flags before laying hands on the foot: rapid growth, size greater than 5 cm, night pain, deep fixation.
  5. Offload. Plantar orthosis with a cut-out under the nodule, cushioning insole, footwear advice. This is the intervention whose effect is the most direct on the complaint.
  6. Inform about the whole pathway. Including radiotherapy, which the patient will not consider spontaneously and which is nonetheless the only treatment validated against placebo10.

What you follow up, and how often

Proposed follow-up. The indicators are those used in the literature on this condition; the intervals reflect common-sense organisation and not a published recommendation.
What is measuredWhyFrequency
Number and size of nodulesThe only objective marker of progression; multiple nodules affect 17 % of patients from the first consultation5Every 2 to 3 months
Pain on weight-bearing on a numerical scaleThis is the primary outcome measure of the LedRad trial, which makes the values comparable with the literature10At each assessment
Walking distance and tolerance of standingDirect functional translation; barefoot walking speed was a secondary outcome of LedRad10At each assessment
Examination of the palmsScreening for an associated Dupuytren's disease, the prevalence of which is multiplied by four in this context6Initial, then annual
Toe mobilityContracture is rare but it marks an advanced form1At each assessment
Tolerance of the orthosisPoorly placed offloading moves the strain instead of removing itAt 3 weeks, then at each assessment

Who to refer to, and when

  • Foot orthopaedic surgeon for disabling pain despite offloading, a large or progressing nodule, toe contracture, or diagnostic doubt. Reminding the surgeon that the extent of the resection governs recurrence16 is legitimate: it is published.
  • Radiation oncologist, via the general practitioner or the specialist; it is the treatment with the best level of evidence, and the patient will never ask for it on their own.
  • Podo-orthotist or podiatrist for the plantar orthosis with selective offloading, which requires an impression suited to the exact location of the nodule.
  • Specialist opinion without delay in the presence of any red flag. Reminder: sarcomas present under the exact guise of plantar fibroma19.

Frequently asked questions

Can this lump disappear on its own?

It is unlikely. Ledderhose disease is a fibrous proliferation; no regular spontaneous regression is described, and no causal treatment exists2. On the other hand, a nodule can remain stable and painless for years, in which case there is nothing to do, and that is good news that should be announced as such.

Will I get the same thing in my hands?

The link exists and it has been quantified: in the Reykjavík cohort, 15.2 % of men with Dupuytren's disease had plantar nodules versus 3.9 % of controls6, and the presence of Ledderhose disease is among the risk factors for Dupuytren's disease in a Dutch population study7. This justifies examining the palms, not becoming alarmed: most patients will not have both.

Is it a cancer?

No: it is a benign lesion1. But the question is legitimate, because rare malignant tumours can present in exactly the same way19. This is precisely why a mass that grows quickly, that exceeds a few centimetres or that wakes you at night is investigated before it is treated.

Should it be operated on?

Only after failure of conservative treatment915, and never on a painless nodule. The point to know before deciding: recurrence depends on the extent of the resection: 67 % after removal of the nodule alone, 42 % after wide resection, 27 % after fasciectomy16. A partial fasciectomy also led to 17 % scar problems in a series of 18 patients5, which is no small matter under a foot.

Are insoles of any use?

No study has measured it in this disease. The mechanical reasoning is sound (a nodule of the middle third of the arch is compressed at every step between the ground and the bone, and the cut-out removes this compression) and the risk is nil. It is a common-sense intervention, to be offered as such and not as a validated treatment.

Can I keep running?

Nothing forbids it and nothing encourages it: the question has not been studied. The practical guide is weight-bearing pain, which governs. Change the surface, the shoe and the volume before stopping, and adapt the orthosis to the sports shoe, which does not have the same internal volume as an everyday shoe.

Isn't radiotherapy dangerous?

In the phase 3 randomised trial, the adverse effects (erythema, dry skin, burning sensations, transient worsening of pain) were of mild grade in 95 % of cases and resolved in 87 % of patients at eighteen months10. In the long-term follow-up cohort, the most frequent residual effect was dry skin in 15 % of patients11. The decision rests with the doctor; the factual information is given in the session.

Do shockwaves work?

The available literature is a prospective series of six patients and one case report, both without a control group1213. The reported results are favourable and the parameters are published (shockwaves that are focused and of high energy, not radial), but the sample size rules out any conclusion. To be offered, where appropriate, as a therapeutic trial whose level of evidence is stated.

On the same subject

Bibliography

Each reference was individually verified in PubMed: identifier resolved, journal, year, volume and author list checked, abstract read to make sure that the source does establish what is attributed to it.

  1. Stewart BD, Nascimento AF. Palmar and plantar fibromatosis: a review. J Pathol Transl Med 2021;55(4):265-270. DOI 10.4132/jptm.2021.06.14 — PMID 34225446
  2. Veith NT, Tschernig T, Histing T, Madry H. Plantar fibromatosis - topical review. Foot Ankle Int 2013;34(12):1742-1746. DOI 10.1177/1071100713505535 — PMID 24043350
  3. Cohen BE, Murthy NS, McKenzie GA. Ultrasonography of plantar fibromatosis: updated case series, review of the literature, and a novel descriptive appearance termed the “comb sign”. J Ultrasound Med 2018;37(11):2725-2731. DOI 10.1002/jum.14615 — PMID 29603334
  4. Tomac A, Ion AP, Opriș DR et al. Ledderhose's disease: an up-to-date review of a rare non-malignant disorder. Clin Pract 2023;13(5):1182-1195. DOI 10.3390/clinpract13050106 — PMID 37887082
  5. Kadir HKA, Chandrasekar CR. Partial fasciectomy is a useful treatment option for symptomatic plantar fibromatosis. Foot (Edinb) 2017;31:31-34. DOI 10.1016/j.foot.2017.02.002 — PMID 28334642
  6. Gudmundsson KG, Jónsson T, Arngrímsson R. Association of Morbus Ledderhose with Dupuytren's contracture. Foot Ankle Int 2013;34(6):841-845. DOI 10.1177/1071100713475352 — PMID 23386754
  7. Lanting R, van den Heuvel ER, Westerink B, Werker PMN. Prevalence of Dupuytren disease in The Netherlands. Plast Reconstr Surg 2013;132(2):394-403. DOI 10.1097/PRS.0b013e3182958a33 — PMID 23897337
  8. Hindocha S, Stanley JK, Watson S, Bayat A. Dupuytren's diathesis revisited: evaluation of prognostic indicators for risk of disease recurrence. J Hand Surg Am 2006;31(10):1626-1634. DOI 10.1016/j.jhsa.2006.09.006 — PMID 17145383
  9. Young JR, Sternbach S, Willinger M, Hutchinson ID, Rosenbaum AJ. The etiology, evaluation, and management of plantar fibromatosis. Orthop Res Rev 2019;11:1-7. DOI 10.2147/ORR.S154289 — PMID 30774465
  10. de Haan A, van Nes JGH, Kolff MW et al. Radiotherapy for Ledderhose disease: results of the LedRad-study, a prospective multicentre randomised double-blind phase 3 trial. Radiother Oncol 2023;185:109718. DOI 10.1016/j.radonc.2023.109718 — PMID 37211283
  11. de Haan A, van Nes JGH, Werker PMN, Langendijk JA, Steenbakkers RJHM. Radiotherapy for patients with Ledderhose disease: long-term effects, side effects and patient-rated outcome. Radiother Oncol 2022;168:83-88. DOI 10.1016/j.radonc.2022.01.031 — PMID 35101465
  12. Knobloch K, Vogt PM. High-energy focussed extracorporeal shockwave therapy reduces pain in plantar fibromatosis (Ledderhose's disease). BMC Res Notes 2012;5:542. DOI 10.1186/1756-0500-5-542 — PMID 23031080
  13. Fulceri F, Ryskalin L, Morucci G, Busoni F, Soldani P, Gesi M. Pain-relieving effects of shockwave therapy for Ledderhose disease: an ultrasound-based study of an unusual bilateral case. Life (Basel) 2024;14(2):169. DOI 10.3390/life14020169 — PMID 38398678
  14. Flanagan G, Burt N, Reilly IN. Intralesional fenestration and corticosteroid injection for symptomatic Ledderhose disease of the foot: two case reports. SAGE Open Med Case Rep 2021;9:2050313X211011813. DOI 10.1177/2050313X211011813 — PMID 33996088
  15. Fuiano M, Mosca M, Caravelli S et al. Current concepts about treatment options of plantar fibromatosis: a systematic review of the literature. Foot Ankle Surg 2019;25(5):559-564. DOI 10.1016/j.fas.2018.06.001 — PMID 30321942
  16. Anwander H, Weichsel F, Cullmann J, Seidel A, Hayoz A, Krause F. Recurrence rate after wide resection of plantar fibromatosis: a case series and systematic literature review. Foot Ankle Spec 2024;17(2):109-116. DOI 10.1177/19386400211032099 — PMID 34369197
  17. Hammoudeh ZS. Collagenase Clostridium histolyticum injection for plantar fibromatosis (Ledderhose disease). Plast Reconstr Surg 2014;134(3):497e-499e. DOI 10.1097/PRS.0000000000000433 — PMID 25158740
  18. Greenfield AL, Baez AB, Humbyrd CJ et al. Ultrasound-guided collagenase injection therapy of recurrent plantar fibromatosis: a case report. Foot Ankle Orthop 2023;8(4):24730114231201161. DOI 10.1177/24730114231201161 — PMID 37869482
  19. Lockyer MG, Rosen DG. Extraskeletal myxoid chondrosarcoma presenting as a plantar fibroma: case report and review of the literature. Anticancer Res 2015;35(11):6171-6174. PMID 26504046
  20. Touraine S, Bousson V, Kaci R et al. Plantar fibromatosis may adopt the brain gyriform pattern of a low-grade fibromyxoid sarcoma. Foot (Edinb) 2013;23(2-3):88-92. DOI 10.1016/j.foot.2012.12.006 — PMID 23415764
  21. Griffith JF, Wong TY, Wong SM, Wong MW, Metreweli C. Sonography of plantar fibromatosis. AJR Am J Roentgenol 2002;179(5):1167-1172. DOI 10.2214/ajr.179.5.1791167 · PMID 12388493
  22. Velez N, Weinschenk C, Goel A et al. MRI characteristics of plantar fibromas: a large consecutive series from a tertiary care center with symptom analysis. Skeletal Radiol 2026;55(2):391-400. DOI 10.1007/s00256-025-05036-8 · PMID 40958075
  23. Davis J, Near A, Tse J, Doshi R, Wang E, Ortega L, Hurley D, Armstrong DG. Real-world treatment patterns among newly diagnosed patients with plantar fibromatosis in the United States. J Foot Ankle Surg 2026;65(3):95.e1-95.e8. DOI 10.1053/j.jfas.2026.01.004 · PMID 41519372
  24. Seegenschmiedt MH, Micke O, Niewald M et al. DEGRO guidelines for the radiotherapy of non-malignant disorders: part III: hyperproliferative disorders. Strahlenther Onkol 2015;191(7):541-548. DOI 10.1007/s00066-015-0818-2 · PMID 25753848

Method and limitations

Sources searched in PubMed via the NCBI E-utilities services, crossing plantar fibromatosis and Ledderhose disease with epidemiology, imaging, radiotherapy, shockwaves, injections, collagenase and surgery. Each identifier was resolved and each abstract read before citation. Main limitation: only one randomised trial exists in this disease, and it concerns radiotherapy; everything else rests on retrospective series and case reports. The levels of evidence in the table of modalities are an editorial judgement applying GRADE principles, and not a published GRADE assessment; the only learned-society recommendation found is a German radiation oncology consensus (DEGRO 2015), which covers the disease among other non-malignant conditions. One reference was moreover set aside during the work: an article whose title announced a case of bilateral plantar fibromatosis but whose indexed abstract described an entirely different patient: inconsistent metadata, hence not cited. Article written on 14 August 2026.

Behind this article

An author who explains, a reviewer who checks.

How we write and check our content

Anthony Baillon, physiotherapist and co-founder of Physio Learning
✍️ Author

Anthony Baillon

Physiotherapist · co-founder of Physio Learning

Marked for life by his first four-hour lecture without a single image, he took a master’s in instructional design so that it would never happen to anyone again. He hunts down publication bias and unreadable slides with the same intransigence.

PhysiotherapistInstructional designerCare design
Follow on LinkedIn
Robin Vervaeke, head of scientific content at Physio Learning✓ Verified

Robin Vervaeke

Head of scientific content

Physiotherapist specialising in neuro-musculoskeletal practice and holder of a master’s in public health. He checks the methodological rigour of every article: primary sources, levels of evidence, no exceptions.

Neuro-musculoskeletalMSc Public health
Follow on LinkedIn

Share